ClinicalTrials.gg
CompletedNCT00172185Updated Jun 2, 2021Results posted

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

A Phase 3 interventional study of teduglutide 0.05 mg/kg/d and teduglutide 0.10 mg/kg/d in Short Bowel Syndrome, sponsored by Shire. Completed at 21 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-02.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2005, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
5th of 20
65 · median 20
Started
2005
the only one that year
Phase 3
16 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 5th largest by enrollment, is the only one that started in 2005, is one of 16 in phase 3, and was the 2nd registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.

Read the detailed description

Teduglutide is an analog of naturally occurring human glucagon-like peptide-2 (GLP-2), a peptide secreted by L-cells of the distal intestine. GLP-2 is known to increase intestinal and portal blood flow, and inhibit gastric acid secretion. Teduglutide binds to the glucagon-like peptide-2 receptors located in intestinal subpopulations of enteroendocrine cells, subepithelial myofibroblasts and enteric neurons of the submucosal and myenteric plexus. Activation of these receptors results in the local release of multiple mediators including insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF).

This multicenter, double-blind, international, Phase III trial will have a treatment period of 28 weeks. Subjects in this study are those who received teduglutide or placebo in protocol CL0600-004 (NCT00081458). These subjects will receive daily subcutaneous injections of 0.05 milligrams or 0.10 milligrams of teduglutide per kilogram of body weight. Subjects will have visits every 4 to 6 weeks and will be assessed for parenteral nutrition (PN) reduction with a follow-up period of 4 weeks duration for those subjects who do not complete this protocol, or do not enter into the long-term safety extension protocol CL0600-010.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

Keywords

  • Short Bowel Syndrome
  • Parenteral Nutrition
  • SBS
  • Teduglutide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At dosing week 24 of protocol CL0600-004 (NCT00081458), subjects will be reviewed for their participation in this study.

Subjects who meet all of the following criteria can be enrolled in this study:

  • Signed and dated form (ICF) to participate before any study-related procedures are performed
  • Completion of protocol CL0600-004 (NCT00081458)

Exclusion criteria

Exclusion Criteria:

  • History of cancer or lymphoproliferative disease with fewer than 5 years documented disease-free state
  • History of alcohol or drug abuse (within previous year)
  • Prior use of native glucagon-like peptide 2 (GLP-2) within 3 months of screening visit
  • Pregnant or lactating women
  • Any condition or circumstance, which in the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with analysis of the study results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    teduglutide 0.05 mg/kg/d

    0.05 mg/kg/d teduglutide subcutaneous injection

    Drug: teduglutide 0.05 mg/kg/d

  • Experimental
    teduglutide 0.10 mg/kg/d

    0.10 mg/kg/d teduglutide subcutaneous injection

    Drug: teduglutide 0.10 mg/kg/d

Interventions

  • Drugteduglutide 0.05 mg/kg/d

    Drug page: Teduglutide

    0.05 mg/kg/d subcutaneous injection

    Also known as: GATTEX

  • Drugteduglutide 0.10 mg/kg/d

    Drug page: Teduglutide

    0.10 mg/kg/d subcutaneous injection

    Also known as: GATTEX

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving a 20% Reduction at Week 28

    For those subjects who received teduglutide (0.05 or 0.10 mg dose) in Study 004 and the same in Study 005, Parenteral Nutrition (PN) Use at Week 28 was compared to the Baseline Visit of Study 004 to calculate the 20% reduction in PN Use. For those subjects who received placebo in Study 004 and either teduglutide 0.05 or 0.10 mg dose in Study 005, PN Use at Week 28 was compared to the use of PN at Week 24 of Study 004 to calculate the 20% reduction in PN Use.

    Time frame: 28 weeks

Secondary outcomes

  1. Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use

    Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use (Responder Status is Yes or No)

    Time frame: 6 months

07

Results

Posted Apr 23, 2013

Participant flow

10Jan2005 - First Subject Enrolled 24Jan2008 - Last Subject Completed

Participant flow — Overall Study
MilestonePlacebo/0.05Placebo/0.100.05/0.050.10/0.10
Started672527
Completed652023
Not completed0254
Withdrew: Adverse event0134
Withdrew: Physician decision0010
Withdrew: Sponsor decision0100
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryNumber of Subjects Achieving a 20% Reduction at Week 28

For those subjects who received teduglutide (0.05 or 0.10 mg dose) in Study 004 and the same in Study 005, Parenteral Nutrition (PN) Use at Week 28 was compared to the Baseline Visit of Study 004 to calculate the 20% reduction in PN Use. For those subjects who received placebo in Study 004 and either teduglutide 0.05 or 0.10 mg dose in Study 005, PN Use at Week 28 was compared to the use of PN at Week 24 of Study 004 to calculate the 20% reduction in PN Use.

Time frame:
28 weeks
Reported as:
Number · Participants
Number of Subjects Achieving a 20% Reduction at Week 28
ParticipantsPlacebo/0.05Placebo/0.100.05/0.050.10/0.10
Number of Subjects Achieving a 20% Reduction at Week 28531714
SecondaryNumber of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use

Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use (Responder Status is Yes or No)

Time frame:
6 months
Reported as:
Number · participants
Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use
participantsPlacebo/0.05Placebo/0.100.05/0.050.10/0.10
Response Status: Yes421710
Response Status: No25817

Adverse events

Collected over 28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/0.05—2/6 (33.3%)6/6 (100%)
Placebo/0.10—3/7 (42.9%)7/7 (100%)
0.05/0.05—13/25 (52%)22/25 (88%)
0.10/0.10—9/27 (33.3%)26/27 (96.3%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPlacebo/0.05Placebo/0.100.05/0.050.10/0.10
Catheter bacteremiaInfections and infestations1/61/70/251/27
Catheter sepsisInfections and infestations1/60/74/252/27
Catheter site infectionInfections and infestations1/60/70/250/27
Gastric ulcerGastrointestinal disorders0/61/70/250/27
GI haemorrhageGastrointestinal disorders0/61/70/250/27
Pancreatitis chronicGastrointestinal disorders0/61/7—0/27
Catheter related complicationGeneral disorders0/61/71/250/27
CholecystitisHepatobiliary disorders0/61/70/250/27
BronchitisInfections and infestations0/61/70/250/27
Subdiaphragmatic abscessInfections and infestations0/61/70/250/27
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPlacebo/0.05Placebo/0.100.05/0.050.10/0.10
Reproductive system and breast DisordersReproductive system and breast disorders3/60/70/250/27
DiarrheaGastrointestinal disorders2/60/71/251/27
PyrexiaGeneral disorders2/61/70/250/27
ContusionInjury, poisoning and procedural complications2/60/71/252/27
HeadacheNervous system disorders2/61/72/256/27
Abdominal painGastrointestinal disorders0/62/74/253/27
Injection site erythemaGeneral disorders0/62/70/251/27
Renal and urinary disordersRenal and urinary disorders0/62/72/253/27
NauseaGastrointestinal disorders0/60/72/256/27
Skin and subcutaneous tissue disorderSkin and subcutaneous tissue disorders1/60/72/256/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo/0.05Placebo/0.100.05/0.050.10/0.10Total
Mean42.2 ± 14.0656.6 ± 9.7446.7 ± 13.4849.4 ± 14.0448.5 ± 13.61
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/0.05Placebo/0.100.05/0.050.10/0.10Total
Female44101432
Male23151333
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo/0.05Placebo/0.100.05/0.050.10/0.10Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American10326
White57222559
More than one race00000
Unknown or Not Reported00000
08

Study locations

21 sites
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania - Penn Nursing
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Hôpital Erasme
    Brussels, 1070, Belgium
  • St. Paul's Hospital
    Vancouver, British Columbia V6Z1Y6, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B1W8, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G2N2, Canada
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • Hôpital Huriez
    Lille, 59037, France
  • Hôpital de la Croix-Rousse
    Lyon, 69317, France
  • Hôpital Lariboisière
    Paris, 92110, France
  • Academic Medical Center, Department of Endocrinology & Metabolism
    Amsterdam, 1100 DD, Netherlands
  • Pracownia Żywienia
    Olsztyn, 10-561, Poland
  • Samodzielny Publiczny Szpital Kliniczny-Im.prof W.Orłowskiego CMKP
    Warsaw, 00-416, Poland
  • St. Mark's Hospital
    Harrow, HAI3UJ, United Kingdom
09

References and documents

Publications

  • Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011 Jul;60(7):902-14. doi: 10.1136/gut.2010.218271. Epub 2011 Feb 11. PubMed 21317170 ↗
  • O'Keefe SJ, Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol. 2013 Jul;11(7):815-23.e1-3. doi: 10.1016/j.cgh.2012.12.029. Epub 2013 Jan 17. PubMed 23333663 ↗
  • Vipperla K, O'Keefe SJ. Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects. Expert Rev Gastroenterol Hepatol. 2013 Nov;7(8):683-7. doi: 10.1586/17474124.2013.842894. Epub 2013 Oct 17. PubMed 24134154 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2005 to primary completion in Jan 2008, 36 months.

Results were first posted in Apr 2013, 5 years 2 months after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 36 months is close to that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 15, 2005
StartActual
Jan 10, 2005
Primary completionActual
Jan 24, 2008
CompletionActual
Jan 24, 2008
Results first posted
Apr 23, 2013
Last update
Jun 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00172185
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Jan 10, 2005
Primary completion
Jan 24, 2008
Completion
Jan 24, 2008
Results posted
Apr 23, 2013
Last update
Jun 2, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion